natgillin/translations-raw huggingface dataset:
Patients with left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be particularly sensitive to the actions of vasodilators including avanafil (see section 4.4).
Bolesnici s opstrukcijom izlaznog trakta lijevog ventrikula (npr. aortna stenoza, idiopatska hipertrofična subaortna stenoza) i oni s teško oštećenom autonomnom kontrolom krvnog tlaka mogu biti posebno osjetljivi na djelovanja vazodilatatora uključujući avanafil (vidjeti dio 4.4).
Common (may affect up to 1 in 10 people)
Česte (mogu se pojaviti u do 1 od 10 osoba)
Results showed a mean maximum decrease in supine blood pressure of 2/3 mmHg compared to placebo with enalapril and 1/-1 mmHg with amlodipine when avanafil was co-administered.
Rezultati su pokazali srednju vrijednost maksimalnog sniženja krvnog tlaka u ležećem položaju na leđima od 2/3 mmHg u usporedbi s placebom uz enalapril i 1/-1 mmHg uz amlodipin, kada su se primjenjivali istodobno s avanafilom.
Use in men with diabetes Dose adjustments are not required in diabetic patients.
U muškaraca s dijabetesom nisu potrebne prilagodbe doze.
In a single-dose three-way crossover design study evaluating healthy subjects, the mean maximum reduction in diastolic blood pressure was significantly greater following avanafil administered in combination with alcohol than following avanafil alone (3.2 mmHg) or alcohol alone (5.0 mmHg) (see section 4.4).
U ispitivanju jednokratne doze s trostrukim ukrižavanjem u kojemu su se procjenjivali zdravi ispitanici, srednja vrijednost maksimalnog smanjenja dijastoličkog krvnog tlaka bila je značajno veća nakon primjene avanafila u kombinaciji s alkoholom nego nakon primijene samo avanafila (3,2 mmHg) ili samo alkohola (5,0 mmHg) (vidjeti dio 4.4).
Single dose of up to 800 mg of avanafil have been given to healthy subjects and multiple daily doses up to 300 mg have been given to patients.
Zdravi ispitanici dobili su jednokratnu dozu do 800 mg avanafila, dok su bolesnici dobili višekratne dnevne doze do 300 mg.
NAME OF THE MARKETING AUTHORISATION HOLDER Menarini Luxembourg
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Menarini Luxembourg
In in vitro studies in human liver microsomes, avanafil showed a negligible potential for drug-drug interactions with CYP1A1/2, 2A6, 2B6 and 2E1.
U ispitivanjima avanafila in vitro na ljudskim mikrosomima jetre, avanafil je pokazao zanemariv potencijal za interakcije lijekova s CYP1A1/2, 2A6, 2B6 i 2E1.
Avanafil was evaluated in 4 randomized, double-blind, placebo-controlled, parallel group trials of up to 3 months in duration in the general population with ED, in patients with Type 1 or Type 2 diabetes and ED, and in patients with ED following bilateral nerve-sparing radical prostatectomy.
Avanafil je procijenjen u 4 randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja na usporednim skupinama u trajanju do 3 mjeseca u općoj populaciji s ED, u bolesnika s dijabetesom tipa 1 ili tipa 2 i ED te u bolesnika s ED nakon bilateralne radikalne prostatektomije s očuvanjem neurovaskularnog snopa.
Patients with known hereditary degenerative retinal disorders.
Bolesnici s potvrđenim nasljednim degenerativnim poremećajima mrežnice.
Patients with left ventricular outflow obstruction, e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators, including PDE5 inhibitors.
Bolesnici s opstrukcijom izlaznog trakta lijevog ventrikula, npr. aortnom stenozom i idiopatskom hipertrofičnom subaortnom stenozom, mogu biti osjetljivi na djelovanje vazodilatatora, uključujući inhibitore PDE5.
Consumption of alcohol in combination with avanafil can increase the potential for symptomatic hypotension (see section 4.5).
Konzumacija alkohola u kombinaciji s avanafilom može povećati mogućnost simptomatske hipotenzije (vidjeti dio 4.5).
Subjects with mild hepatic impairment (Child-Pugh A) had comparable exposure to subjects with normal hepatic function when a single dose of 200 mg avanafil was administered.
Ispitanici s blagim oštećenjem jetre (Child-Pugh A) imali su usporedivu izloženost kao i ispitanici s normalnom funkcijom jetre kada im je primijenjena jednokratna doza avanafila od 200 mg.
Metabolism and nutrition disorders
Poremećaji metabolizma i prehrane giht
8x1 tablets
8x1 tableta
• blurred vision.
• zamućen vid.
Also do not take Spedra if you are taking medicines for HIV or AIDS such as ritonavir, indinavir, saquinavir, nelfinavir or atazanavir or if you are taking medicines for fungal infections such as ketoconazole, itraconazole or voriconazole or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin (see beginning of section 2 under ‘Do not take Spedra').
Također, nemojte uzimati Spedru ako uzimate lijekove protiv HIV-a ili AIDS-a kao što su ritonavir, indinavir, sakvinavir, nelfinavir ili atazanavir ili ako uzimate lijekove protiv gljivičnih infekcija kao što su ketokonazol, itrakonazol ili vorikonazol ili određene antibiotike protiv bakterijskih infekcija, kao što su klaritromicin ili telitromicin (vidjeti početak dijela 2 'Nemojte uzimati lijek Spedra').
In a rat fertility and early embryonic development trial, a decrease in fertility and sperm motility, altered estrous cycles, and an increased percentage of abnormal sperm occurred at 1000 mg/kg/day, a dose which also caused parental toxicity in the treated males and females.
U ispitivanju plodnosti i ranog embrionalnog razvoja štakora, smanjenje plodnosti i pokretljivosti spermija, promijenjenih ciklusa estrusa i povećanog postotka abnormalne sperme javljale su se pri dozi od 1000 mg/kg/dan, koja je u liječenih ženki i mužjaka uzrokovala roditeljsku toksičnost.
The co-administration of type 5 phosphodiesterase (PDE5) inhibitors, including avanafil, with guanylate cyclase stimulators, such as riociguat is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
Istodobna primjena inhibitora fosfodiesteraze tipa 5 (PDE5), uključujući avanafil, sa stimulatorima gvanilat ciklaze poput riocigvata, je kontraindicirana, jer može dovesti do simptomatske hipotenzije (vidjeti dio 4.5).
Concomitant use of other treatments for erectile dysfunction The safety and efficacy of combinations of Spedra and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied.
Istodobna primjena drugih liječenja za erektilnu disfunkciju Sigurnost i djelotvornost Spedre u kombinaciji s drugim inhibitorima PDE5 ili drugim liječenjima erektilne disfunkcije nisu ispitane.
The concomitant use of alpha-blockers and avanafil may lead to symptomatic hypotension in some patients due to additive vasodilatory effects (see section 4.5).
Istodobna primjena alfa blokatora i avanafila može u nekih bolesnika dovesti do simptomatske hipotenzije zbog dodatnih vazodilatacijskih učinaka (vidjeti dio 4.5).
Avanafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
Avanafil se uklanja uglavnom putem jetrenih mikrosomalnih izoenzima CYP3A4 (glavni put) i CYP2C9 (manje važan put).
Angina pectoris Tachycardia
Srčani poremećaji palpitacije angina pektoris tahikardija
Dose adjustments are not required in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 mL/min).
Prilagodbe doze nisu potrebne u bolesnika s blagim do umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 ml/min).
Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Pretklinička ispitivanja su pokazala aditivni učinak na sniženje sistemskog krvnog tlaka kada su se inhibitori PDE5 primjenjivali u kombinaciji s riocigvatom.
• If you are taking medicines for fungal infections such as ketoconazole, itraconazole or voriconazole or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin
• ako uzimate lijekove protiv gljivičnih infekcija kao što su ketokonazol, itrakonazol ili vorikonazol ili određene antibiotike protiv bakterijskih infekcija, kao što su klaritromicin ili telitromicin
Spedra is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min) (see sections 4.3 and 5.2).
Spedra je kontraindicirana u bolesnika s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) (vidjeti dijelove 4.3 i 5.2).
Seasonal allergy
Poremećaji imunološkog sustava sezonska alergija
Spedra is contraindicated in patients with severe hepatic impairment (Child Pugh class C) (see sections 4.3 and 5.2).
Spedra je kontraindicirana u bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C) (vidjeti dijelove 4.3 i 5.2).
In a rat pre- and post-natal development study, pups exhibited persistent decreases in body weight at 300 mg/kg/day and higher (approximately 15 times the MRHD on a mg/m basis) and delayed sexual development at 600 mg/kg/day (approximately 29 times the MRHD on a mg/m basis).
U ispitivanju prenatalnog i postnatalnog razvoja, mladunci su pokazali perzistentna smanjenja u tjelesnoj težini pri dozi od 300 mg/kg/dan i višoj (otprilike 15 puta većoj dozi od MRHD na bazi mg/m2) i odgođen spolni razvoj pri dozi od 600 mg/kg/dan (približno 29 puta većoj dozi od MRHD na bazi mg/m
4x1 tablets 8x1 tablets 12x1 tablets 2x1 tablets
4x1 tableta 8x1 tableta 12x1 tableta 2x1 tableta
No effects on fertility or sperm parameters were noted at doses up to 300 mg/kg/day (in male rats 9 times human exposure based on unbound AUC at a dose of 200 mg).
Nisu uočeni učinci na plodnost ili parametre sperme pri dozama do 300 mg/kg/dan (u mužjaka štakora izloženost 9 puta veća od izloženosti u ljudi na temelju vrijednosti AUC-a nevezanog avanafila u dozi od 200 mg).
Uncommon (may affect up to 1 in 100 people)
Manje česte (mogu se pojaviti u do 1 na 100 osoba)
In clinical studies, riociguat has shown to augment the hypotensive effects of PDE5 inhibitors.
U kliničkim se ispitivanjima pokazalo da riocigvat pojačava hipotenzivni učinak inhibitora PDE5.
Breast-feeding There are no data on the use of avanafil during breast-feeding.
Dojenje Nema podataka o primjeni avanafila tijekom dojenja.
In pregnant rabbits, no teratogenicity, embryotoxicity or fetotoxicity was observed at doses up to 240 mg/kg/day (approximately 23 times the MRHD on a mg/m basis.
U trudnih kunića, teratogenost, embriotoksičnost ili fetotoksičnost nisu opaženi pri dozama do 240 mg/kg/dan (približno 23 puta veća doza od MRHD na bazi mg/m 2).
Concomitant use of riociguat with PDE5 inhibitors, including avanafil, is contraindicated (see section 4.3).
Istodobna primjena riocigvata s inhibitorima PDE5, uključujući avanafil, je kontraindicirana (vidjeti dio 4.3).
No cases were reported during clinical trials of avanafil.
Tijekom kliničkih ispitivanja avanafila nije bilo prijavljenih slučajeva.
One episode of “syncope” was observed in placebo and one episode on 100 mg of avanafil in phase III clinical trials.
U kliničkim ispitivanjima faze III, opažena je jedna epizoda ”sinkope” uz placebo i jedna uz avanafil u dozi od 100 mg.
There were no treatment-related testicular findings in mice or rats treated with doses up to 600 or 1000 mg/kg/day for 2 years, and no testicular findings in dogs treated with avanafil for 9 months at exposures 110 times human exposure at the Maximum Recommended Human Dose (MRHD).
U miševa ili štakora liječenih dozama do 600 ili 1000 mg/kg/dan tijekom 2 godine nije bilo nalaza testisa povezanih s liječenjem, nije ih bilo ni u pasa liječenih avanafilom 9 mjeseci pri izloženostima 110 puta većim od ljudske izloženosti prema maksimalnoj preporučenoj dozi u ljudi (engl.
Penis disorder Spontaneous penile erection
Poremećaji reproduktivnog sustava i dojki poremećaj penisa spontana erekcija penisa genitalni pruritus
The potential effect of CYP inducers, especially inducers of CYP3A4 (e.g. bosentan, carbamazepine, efavirenz, phenobarbital and rifampicin) on the pharmacokinetics and efficacy of avanafil has not been evaluated.
Nije procijenjen potencijalni učinak CYP induktora, osobito induktora CYP3A4 (npr. bosentan, karbamazepin, efavirenz, fenobarbital i rifampicin) na farmakokinetiku i djelotvornost avanafila.
Patients who are using any form of organic nitrate or nitric oxide donors (such as amyl nitrite) (see section 4.5).
Bolesnici koji primjenjuju bilo koji oblik organskog nitrata ili lijekovi koji su donori dušikova oksida (poput amil-nitrita) (vidjeti dio 4.5).
2x1 tablets 4x1 tablets 8x1 tablets 12x1 tablets
2x1 tableta 4x1 tableta 8x1 tableta 12x1 tableta
In patients receiving concomitant treatment with moderate CYP3A4 inhibitors (including erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil), the maximum recommended dose of avanafil should not exceed 100 mg, with an interval of at least 48 hours between doses (see section 4.5).
U bolesnika koji se istodobno liječe umjerenim inhibitorima CYP3A4 (uključujući eritromicin, amprenavir, aprepitant, diltiazem, flukonazol, fosamprenavir i verapamil), najviša preporučena doza avanafila ne smije prelaziti 100 mg, s razmakom između doza od najmanje 48 sati (vidjeti dio 4.5).
A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.
Da bi se dijagnosticirala erektilna disfunkcija i odredili mogući podležeći uzroci, prije razmatranja farmakološkog liječenja potrebno je uzeti anamnezu i provesti tjelesni pregled.
• an abnormal blood test result for creatinine, a chemical excreted in the urine, and a measure of kidney function
• poremećeni nalaz pretrage krvi za kreatinin, kemijske tvari koja se izlučuje u mokraći i koja je mjera funkcije bubrega
Consequently, co-administration of avanafil with potent CYP3A4 inhibitors is contraindicated (see sections 4.2, 4.3 and 4.4).
Posljedično tome, kontraindicirana je istodobna primjena avanafila s potentnim inhibitorima CYP3A4 (vidjeti dijelove 4.2, 4.3 i 4.4).
Patients with severe renal impairment (creatinine clearance < 30 mL/min).
Bolesnici s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min).
amiodarone or sotalol
nelfinavir ili atazanavir
Hypotension has been reported post marketing with other PDE5 inhibitors, and dizziness, a symptom commonly caused by lowered blood pressure, has been reported in clinical trials with avanafil (see section 4.5).
Hipotenzija je prijavljena nakon stavljanja lijeka u promet uz druge inhibitore PDE5, a u kliničkim ispitivanjima avanafila prijavljena je omaglica, simptom obično uzrokovan sniženjem krvnog tlaka (vidjeti dio 4.5).
Avanafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
U bolesnika s anatomskom deformacijom penisa (kao što su angulacija kavernozna fibroza ili Peyronieova bolest) ili u bolesnika sa stanjima zbog kojih postoji veća mogućnost pojave prijapizma (kao što su anemija srpastih stanica, multipli mijelom ili leukemija) avanafil treba primjenjivati s oprezom.
Amlodipine (5 mg daily) increased avanafil 200 mg single-dose Cmax and AUC by approximately 28% and 60%, respectively.
Amlodipin (5 mg dnevno) je povećao Cmax doze avanafila od 200 mg približno za 28%, a AUC-a za 60%.
There are no data available for subjects with severe renal insufficiency or end-stage renal disease on haemodialysis.
Nema dostupnih podataka za ispitanike s teškom insuficijencijom bubrega ili bubrežnom bolešću u završnoj fazi na hemodijalizi.
Effects of avanafil on other medicinal products
Učinci avanafila na druge lijekove
• riociguat
• riocigvat
In the general population with ED, the mean percentage of attempts resulting in successful intercourse was approximately 47%, 58%, and 59% for the 50 mg, 100 mg, and 200 mg avanafil groups, respectively, as compared with approximately 28% for placebo.
U općoj populaciji sa ED, srednja vrijednost postotka pokušaja koji su rezultirali uspješnim spolnim odnosom bila je približno 47%, 58% odnosno 59% za dozu 50 mg, 100 mg odnosno 200 mg u skupinama koje su primale avanafil u usporedbi s približno 28% za placebo.
• pain or discomfort in the lower abdomen
• bol ili nelagoda u donjem dijelu trbuha
Some men taking medicines like Spedra have had problems with their sight and hearing - see “Serious side effects” in section 4 for more details.
Neki muškarci koji uzimaju lijekove poput Spedre imali su probleme s vidom i sluhom - za više pojedinosti vidjeti „Ozbiljne nuspojave“ u dijelu 4. Nije poznato jesu li ti problemi izravno povezani sa Spedrom, drugim bolestima koje možda imate ili s kombinacijom čimbenika.
Therefore, administration of avanafil to patients who are using any form of organic nitrate or nitric oxide donor (such as amyl nitrite) is contraindicated.
Stoga je primjena avanafila kontraindicirana u bolesnika koji uzimaju bilo koji oblik organskog nitrata ili donora dušikova oksida (poput amil-nitrita).
Haematuria, haematospermia and penile haemorrhage has been reported in a small number of postmarketing and clinical trial cases with other PDE5 inhibitors.
Hematurija, hematospermija i hemoragija penisa prijavljene su u malom broju slučajeva nakon stavljanja lijeka u promet i u kliničkim ispitivanjima s drugim inhibitorima PDE5.
In the Time to onset study, avanafil demonstrated statistically significant improvement in the primary efficacy variable (average per subject proportion of successful responses by time after dose administration, to the Sexual Encounter Profile 3 - SEP3) as compared with placebo, resulting in successful intercourse in 24.71% of the attempts for the 100 mg dose and 28.18% for the 200 mg dose at approximately 15 minutes after dosing compared to 13.78% for placebo.
U ispitivanju koje je procjenjivalo vrijeme do početka djelovanja, avanafil je pokazao statistički značajno poboljšanje što se tiče primarne varijable djelotvornosti (prosječni udio uspješnih odgovora po ispitaniku prema vremenu nakon primjene doze, prema upitniku Sexual Encounter Profile 3SEP3) u usporedbi s placebom, što je rezultiralo uspješnim spolnim odnosom otprilike 15 minuta nakon doziranja u 24,71% pokušaja uz dozu od 100 mg i 28,18% uz dozu od 200 mg u usporedbi s 13,78% na placebu.
Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking avanafil.
Kada se uzima avanafil, postupni povišenje doze alfa blokatora može biti povezano s daljnjim snižavanjem krvnog tlaka.
Pharmacotherapeutic group: Urologicals; Drugs used in erectile dysfunction.
Farmakoterapijska skupina: Lijekovi koji djeluju na mokraćni sustav, pripravci koji se primjenjuju kod erekcijske disfunkcije.
In patients receiving stable doxazosin treatment, the placebo-subtracted mean maximum decreases in standing and supine systolic blood pressure following avanafil dosing were 2.5 mmHg and 6.0 mmHg, respectively.
U bolesnika koji su primali stabilno liječenje doksazosinom, za placebo oduzeta srednja vrijednost maksimalnih smanjenja sistoličkog krvnog tlaka u stojećem i ležećem položaju na leđima, nakon doziranja avanafila bilo je 2,5 mmHg odnosno 6,0 mmHg.
Influenza Nasopharyngitis
Infekcije i infestacije gripa nazofaringitis
Other moderate CYP3A4 inhibitors (e.g. amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil) would be expected to have similar effects.
Očekuje se da će drugi umjereni inhibitori CYP3A4 (npr. amprenavir, aprepitant, diltiazem, flukonazol, fosamprenavir i verapamil) imati slične učinke.
The concomitant use of potent CYP3A4 inhibitors (e.g. ketoconazole and ritonavir) is associated with increased plasma exposure of avanafil (see section 4.5).
Istodobna primjena potentnih inhibitora CYP3A4 (npr. ketokonazol i ritonavir) povezana je s povećanom izloženošću avanafilu u plazmi (vidjeti dio 4.5).
The repeated oral administration of avanafil 100 mg over a period of 26 weeks to healthy volunteers and adult males with mild erectile dysfunction was not associated with any untoward effects on sperm concentration, count, motility, or morphology.
Ponavljana primjena avanafila od 100 mg kroz usta kod zdravih dobrovoljaca i odraslih muškaraca s blagom erektilnom disfunkcijom tijekom 26 tjedana nije bila povezana s neželjenim učincima na koncentraciju, broj, pokretljivost ili morfologiju spermija.
• feeling sleepy or very tired
• osjećaj pospanosti ili velikog umora
In a clinical trial performed in healthy volunteers and adult males with mild erectile dysfunction, the daily administration of avanafil 100 mg oral doses over a period of 26 weeks was not associated with any untoward effects on sperm concentration, count, motility, or morphology .
U kliničkom ispitivanju na zdravim dobrovoljcima i odraslim muškarcima s blagom erektilnom disfunkcijom, dnevna primjena peroralne doze avanafila od 100 mg u periodu od 26 tjedana nije bila povezana s neželjenim učincima na koncentraciju, broj, pokretljivost ili morfologiju spermija.
In pregnant rats, no evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed at doses up to 300 mg/kg/day (approximately 15 times the MRHD on a mg/m basis in a 60 kg subject).
U trudnih štakorica, nisu opaženi dokazi za teratogenost, embriotoksičnost ili fetotoksičnost pri dozama do 300 mg/kg/dan (približno 15 puta veća doza od MRHD na bazi mg/m u ispitanika od 60 kg).
EU/1/13/841/008 4 tablets EU/1/13/841/009 8 tablets EU/1/13/841/010 12 tablets EU/1/13/841/011 2 tablets
EU/1/13/841/008 4 tablete EU/1/13/841/009 8 tableta EU/1/13/841/010 12 tableta EU/1/13/841/011 2 tablete
EU/1/13/841/004 2 tablets EU/1/13/841/005 4 tablets EU/1/13/841/006 8 tablets EU/1/13/841/007 12 tablets
EU/1/13/841/004 2 tablete EU/1/13/841/005 4 tablete EU/1/13/841/006 8 tableta EU/1/13/841/007 12 tableta
• If you have a physical condition that affects the shape of your penis (such as angulation,
• ako imate tjelesno stanje koje utječe na oblik penisa (kao što su angulacija, Peyroniejeva bolest ili kavernozna fibroza)
Priapism has been reported in a small number of post-marketing and clinical trial cases with other PDE5 inhibitors.
Prijapizam je prijavljen u malom broju slučajeva nakon stavljanja lijeka u promet i u kliničkim ispitivanjima s drugim inhibitorima PDE5.
• swelling in the feet or ankles
• oticanje stopala ili gležnjeva
EU/1/13/841/003 12 tablets
EU/1/13/841/003 12 tableta
CYP3A4 substrate
Supstrati CYP3A4
Medicinal products reducing systemic blood pressure As a vasodilator, avanafil may reduce systemic blood pressure.
Kao vazolidatator, avanafil može sniziti sistemski krvni tlak.
• fast heart beat
• ubrzani srčani otkucaji
EU/1/13/841/002 8 tablets
EU/1/13/841/002 8 tableta
In men with either Type 1 or Type 2 diabetes mellitus, the mean percentage of attempts resulting in successful intercourse was approximately 34% and 40% for the 100 mg and 200 mg avanafil groups, respectively, compared to approximately 21% for the placebo group.
U muškaraca s dijabetes melitusom tipa 1 ili tipa 2, srednja vrijednost postotka pokušaja koja je rezultirala uspješnim spolnim odnosom bila je približno 34% odnosno 40% za skupinu koja je primala 100 mg odnosno 200 mg avanafila, u usporedbi s približno 21% za placebo skupinu.
inhibitors') including amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil.
CYP3A4“) uključujući amprenavir, aprepitant, diltiazem, flukonazol, fosamprenavir i verapamil
Ketoconazole (400 mg daily), a selective and highly potent inhibitor of CYP3A4, increased avanafil 50 mg single-dose Cmax and exposure (AUC) equal to 3-fold and 14-fold respectively and prolonged the half-life of avanafil to approximately 9 hours.
Ketokonazol (400 mg dnevno), selektivni i visoko potentni inhibitor CYP3A4, povećao je Cmax jednokratne doze avanafila od 50 mg i izloženost (AUC) jednaku 3 puta odnosno 14 puta i produljio poluvijek avanafila na približno 9 sati.